Literature DB >> 30787206

PUM2 Promotes Glioblastoma Cell Proliferation and Migration via Repressing BTG1 Expression.

Yuanyu Wang1, Weili Sun1, Jiankai Yang1, Liang Yang1, Chen Li1, Hongjiang Liu1, Xiaopeng Liu1, Baohua Jiao1.   

Abstract

PUM2, an RNA binding protein, is known to promote stem cell proliferation via repressing expressions of cell cycle genes. Similar with stem cells, malignant cells are characterized by unlimited proliferation and remote migration. However, roles of PUM2 in cancer development are controversial. Here, we investigated PUM2's role in glioblastoma development and its relationship with the cell cycle regulator BTG1. Immunoblotting and RT-qPCR were used to evaluate protein expression level and transcript level, respectively. ShRNAs were designed to knock down PUM2 and BTG1 expression. CCK-8 assay was used to evaluate cell viability. Cell migration assay and evasion assay were used to evaluate metastatic capability of glioblastoma cell. RNA pull-down assay and RNA immunoprecipitation assay were used to test the interaction between PUM2 and BTG1 3'UTR. PUM2 expression is elevated in glioblastoma tumor tissues as well as glioblastoma cell lines. PUM2 knockdown remarkably suppresses glioblastoma cell proliferation and migration. In addition, PUM2 knockdown increases BTG1 expression. RNA pull-down assay and RNA immunoprecipitation assay show PUM2 binds to BTG1 3'UTR directly. Furthermore, knockdown of BTG1 reverses the effect of PUM2 knockdown on glioblastoma cell proliferation and migration. Our results suggest that PUM2 promote glioblastoma development via repressing BTG1 expression.Key words: PUM2, BTG1, glioblastoma, cell proliferation, metastasis.

Entities:  

Keywords:  BTG1; PUM2; cell proliferation; glioblastoma; metastasis

Mesh:

Substances:

Year:  2019        PMID: 30787206     DOI: 10.1247/csf.18030

Source DB:  PubMed          Journal:  Cell Struct Funct        ISSN: 0386-7196            Impact factor:   2.212


  6 in total

1.  BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma.

Authors:  Yibing Li; Jianing Huo; Junjian He; Yunzheng Zhang; Xiaoxin Ma
Journal:  Cancer Cell Int       Date:  2020-10-07       Impact factor: 5.722

2.  LncRNA TTN‑AS1 promotes endometrial cancer by sponging miR‑376a‑3p.

Authors:  Longde Shen; Yinyin Wu; Ailu Li; Lichun Li; Longyuan Shen; Qiuxia Jiang; Qiuxia Li; Zhifen Wu; Liji Yu; Xiaohong Zhang
Journal:  Oncol Rep       Date:  2020-07-15       Impact factor: 3.906

3.  Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.

Authors:  Lei Xu; Bin Zhang; Wenlan Li
Journal:  Mol Med Rep       Date:  2021-02-12       Impact factor: 2.952

4.  Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.

Authors:  Donatella Conconi; Serena Redaelli; Andrea Alberto Lissoni; Chiara Cilibrasi; Patrizia Perego; Eugenio Gautiero; Elena Sala; Mariachiara Paderno; Leda Dalprà; Fabio Landoni; Marialuisa Lavitrano; Gaia Roversi; Angela Bentivegna
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

5.  Comprehensive Analysis of Differentially Expressed Profiles of mRNA N6-Methyladenosine in Colorectal Cancer.

Authors:  Na Li; Qin Guo; Qiao Zhang; Bai-Jun Chen; Xiao-An Li; Yan Zhou
Journal:  Front Cell Dev Biol       Date:  2022-01-07

6.  RNA binding protein PUM2 promotes hepatocellular carcinoma proliferation and apoptosis via binding to the 3'UTR of BTG3.

Authors:  Zhenhua Liu; Chunye Lv
Journal:  Oncol Lett       Date:  2022-08-17       Impact factor: 3.111

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.